Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine

- Potentially first biomarker-guided schizophrenia therapeutic

SAN DIEGO, March 3, 2015 /PRNewswire/ -- Denovo Biopharma, LLC, today announced that it has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly and Company (NYSE:  LLY). Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data, and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms. 

Denovo Biopharma provides novel, proprietary biomarker approaches to personalized drug development, including re-evaluating drugs that failed in general patient populations. The company has the first platform for de novo genomic biomarker discovery using archived clinical samples. By retrospectively identifying biomarkers correlated with responses to drugs, Denovo enables clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. www.denovobiopharma.com.

Pomaglumetad was primarily developed and tested in schizophrenia, including in Phase 2 and Phase 3 clinical trials. Predefined sub-population analysis and post-hoc analysis across multiple studies identified a meaningful subset of patients who showed significantly improved outcomes, although pomaglumetad did not meet the primary endpoint in the intent-to-treat population in Phase 3 studies.  Denovo will use its proprietary platform to identify genetic biomarkers as a companion diagnostic to screen for appropriate patient subsets in future clinical trials and eventual commercialization.

"Denovo continues to acquire late-stage medicines to successfully develop with its integrated companion diagnostic and therapeutic development approach, including the acquisition of enzastaurin, a late-stage oncology therapeutic, in September 2014.  Lilly is a world leader in the development of neuroscience drugs and will be a valuable collaborator in pomaglumetad's continued development," said Michael F. Haller, Ph.D., Denovo Biopharma's Chief Operating Officer.

About Pomaglumetad Methionil

Pomaglumetad Methionil (DB103, formerly LY2140023) is a novel glutamatergic-based investigational agent that does not interact with select central nervous system receptors that are thought to be responsible for many of the potential adverse events associated with some antipsychotic drugs which could compromise the treatment of patients with schizophrenia. 

About Denovo Biopharma

Denovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to personalized drug development, including re-evaluating medicines that have failed in general patient populations and studying them in the original indication in biomarker-selected sub-populations. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology may be especially useful for compounds with suboptimal late-stage trial results.  By identifying biomarkers correlated with patients' responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations with increased likelihood of success. For additional information please visit www.denovobiopharma.com.

Contact:
Michael Haller, Chief Operating Officer
Denovo Biopharma, LLC
(858) 876-4012
[email protected]

Logo - http://photos.prnewswire.com/prnh/20140820/138306

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/denovo-biopharma-licenses-late-stage-neuroscience-drug-from-lilly-for-development-as-a-personalized-medicine-300043642.html

SOURCE Denovo Biopharma, LLC

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.